Back to results
UnknownPhase 2

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

NCT04452370

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Cancer Institute & Hospital. Chinese Academy of Medical Sciences

Beijing, China

View on ClinicalTrials.gov
Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer — TrialFind